
IndraLab
Statements
Hydroxychloroquine glycosylates ACE2. 32 / 32
|
32
reach
"The potential use of CQ and HCQ in COVID-19 was initiated by in vitro studies, in which both CQ and HCQ were found to inhibit the fusion of SARS-CoV-2 and the host cell membranes, inhibit the glycosylation of the cellular ACE2 receptor (the binding site of SARS-CoV-2), and block the transport of SARS-CoV-2 from early endosomes to endolysosomes [3] [4] [5]."
| DOI
reach
"Chloroquine and hydroxychloroquine reduce the glycosylation of the ACE2 receptor and the viral penetration into the cell, due to the alcalisation of endocytic compartments -- when not glycosylated, they will have lower affinity towards the viral spike proteins, which probably impedes the virus -- receptor binding, resulting in the inhibition of the infection development [55]."
reach
"There are many ongoing clinical trials which may provide more information on this issue.At the beginning of COVID-19 pandemic, scientists discovered in in-vitro studies that Chloroquine (CQ) and Hydroxychloroquine (HCQ) can inhibit glycosylation of ACE2 receptors [77] and block SARS-CoV-2 transfer from primary endosomes to intracellular lysosomes, thus potentially preventing the release of viral genome [78]."
reach
"Also, postprandial glucose levels were normal during the hypoglycemic period.HCQ is an antimalarial drug with immunomodulatory effects and widely used for rheumatic diseases.Also, previous studies have shown that HCQ interferes with the glycosylation of ACE-2, the receptor of SARS-CoV-2, and inhibits viral fusion into cells 2,3 ."
reach
"In addition to its immunomodulant and anti-inflammatory effects, hydroxychloroquine can interfere with the glycosylation of SARS-CoV-2 spike proteins and ACE2 receptors, blocking, in in vitro experimental models, viral entry [26], so that its empiric prophylactic use among patients and healthcare workers at high risk of infection has been recently advocated by the Indian Council of Medical Research (https://icmr.nic.in/content/covid-19)."